the firm's post-grant practitioners are some of the most experienced in the country.


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Use of ITC in Life Sciences

  • December 15, 2022
  • Article
  • Life Sciences News - December 2022 Newsletter

Associated People

The International Trade Commission remains an active venue for medical devices and other life science patents under 19 U.S.C. § 1337 (“337”). While the ITC is not attractive for ANDA cases where patentees often want to take benefit the 30 month stay of generic approval which is not available in ITC actions, its relatively quick procedures, approximately 16 months from institution to  final decision make it attractive to cases where 35 USC 271(e)(2) are not available. Such cases include medical devices, processes of synthesizing pharmaceuticals including biologics. Of the 11 product categories used by the ITC to categorize technologies, excluding “other”, the pharmaceuticals and medical devices had third the greatest number of petitions instituted at 12 in fiscal year 2022 .   Interest in the ITC as a venue increased markedly beginning in 2012.  The ITC is generally viewed as a pro-patentee forum. Not only patent infringement actions can be brought at the ITC but also trade secret actions. In January 2022 the ITC instituted an investigation for a violation stemming from alleged misuse of AbbVie trade secrets by Alvotech related to its production of a Humira biosimilar. The short pendency of the investigations is attractive for biosimilars to thwart a successful launch of a biosimilar.